Form 4: Pacira BioSciences Director Mark Kronenfeld Receives Significant Equity Compensation Grant

Pacira BioSciences, Inc. Director Mark A. Kronenfeld was granted 9,999 restricted stock units and options to purchase 11,279 shares of common stock as part of his compensation.

Summary

• Mark A. Kronenfeld, a Director of Pacira BioSciences, Inc. (PCRX), acquired 9,999 shares of common stock in the form of restricted stock units (RSUs) on June 11, 2025.
• These RSUs were granted at a price of $0 per unit and represent the contingent right to receive one share of the issuer's common stock for each unit.
• The RSUs are scheduled to vest on June 11, 2026, provided that Mr. Kronenfeld remains in continuous service with Pacira BioSciences through that date.
• Following this transaction, Mr. Kronenfeld beneficially owns 34,901 shares of common stock directly.
• Additionally, Mr. Kronenfeld was granted stock options to acquire 11,279 shares of common stock on June 11, 2025, with an exercise price of $24.34 per share.
• These stock options also vest and become exercisable on June 11, 2026, contingent upon his continuous service with the company.
• The stock options have an expiration date of June 11, 2035.
• Following this transaction, Mr. Kronenfeld beneficially owns 11,279 derivative securities (stock options) directly.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive as it represents routine equity compensation for a director, aligning their interests with shareholders. It is not a direct indicator of company performance but a standard governance practice.

Positives

• The grant of restricted stock units and stock options to a director aligns their financial interests with those of the shareholders, encouraging long-term value creation.
• Equity compensation is a standard practice that helps attract and retain qualified board members.

Risks

• The restricted stock units and stock options are subject to forfeiture if the reporting person's continuous service with the issuer terminates before the vesting date of June 11, 2026.

Future Outlook

The future outlook for the granted equity is contingent upon the continuous service of Director Mark A. Kronenfeld with Pacira BioSciences, Inc. through the vesting date of June 11, 2026. The stock options have an expiration date of June 11, 2035.

Industry Context

The granting of equity compensation, such as restricted stock units and stock options, to non-employee directors is a common and widely accepted practice across publicly traded companies, particularly within the biotechnology and pharmaceutical sectors. This method of compensation is designed to align the interests of the board members with the long-term performance and shareholder value of the company.

Comparison to Industry Standards

• Granting equity compensation, such as restricted stock units and stock options, to non-employee directors is a common and widely accepted practice across publicly traded companies in the biotechnology and pharmaceutical sectors, aligning director incentives with long-term shareholder value.
• The structure of these grants, including vesting periods tied to continuous service, is typical for director compensation plans in the industry.

Related Party Transactions

• The grants of restricted stock units and stock options to Director Mark A. Kronenfeld represent standard equity compensation for a non-employee director, aligning his interests with the company's performance and are a common form of related party transaction in corporate governance.

Stakeholder Impact

• Shareholders: The equity grants align the director's interests with long-term shareholder value, potentially leading to more shareholder-centric decision-making.
• Employees: No direct impact on general employees is indicated by this filing.

Next Steps

• The restricted stock units and stock options are expected to vest on June 11, 2026, provided Director Mark A. Kronenfeld remains in continuous service with the company.

Key Dates

Keywords

Pacira BioSciences, PCRX, SEC Form 4, Insider Transaction, Director Compensation, Restricted Stock Units, Stock Options, Equity Grant, Beneficial Ownership